Aardvark Therapeutics halted its Phase 3 HERO trial for ARD-101, a drug for Prader-Willi Syndrome, due to serious cardiac safety risks. This announcement caused the company's shares to drop 56%, triggering an investigation by Hagens Berman into possible investor misinformation. The firm is examining whether Aardvark misled investors about the drug's safety, efficacy, and FDA communications. Investors with losses or relevant information are encouraged to come forward as the company delays trial data release beyond Q3 2026.
Bluejay Diagnostics completed a private placement raising $8.5 million upfront, with potential additional proceeds of $15.2 million if warrants are fully exercised. The funds will support FDA approval processes, including clinical studies, and genera...
Bitcoin has fallen 50% from its all-time high, erasing about $988 billion in market value due to a mix of market-specific and macroeconomic pressures. Significant ETF outflows in the U.S. signal growing investor caution, while ongoing geopolitical te...
After AI revealed a critical flaw in Zcash's cryptographic system causing a 46% price crash, concerns arose about XRP facing a similar fate. However, RippleX developer J. Ayo Akinyele explained that XRP Ledger's upcoming privacy upgrade, Confidential...
Bitcoin treasury companies have seen a combined market value drop of $62 billion, falling from $134 billion to $72 billion, as Bitcoin trades between $60,000 and $63,000, well below previous highs. Strategy Inc. (formerly MicroStrategy) suffered the ...
Argentina's investigation into $4.78 million in Libra token transactions has been halted because the Specialized Cybercrime Prosecutor’s Office (UFECI) lacks the necessary software to conduct a detailed forensic analysis of the wallets involved. Pros...
